Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children.
Tsai TA, Tsai CK, Kuo KC, Yu HR.
J Microbiol Immunol Infect. 2021 Aug;54(4):557-565. doi: 10.1016/j.jmii.2020.10.002. Epub 2020 Oct 17.
Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.
Lee H, Yun KW, Lee HJ, Choi EH.
Expert Rev Anti Infect Ther. 2018 Jan;16(1):23-34. doi: 10.1080/14787210.2018.1414599. Epub 2017 Dec 11.
Chest imaging classification in Mycoplasma pneumoniae pneumonia is associated with its clinical features and outcomes.
Huang X, Gu H, Wu R, Chen L, Lv T, Jiang X, Li H, Guo B, Liu J, Li D, Zhao D, Liu F.
Respir Med. 2024 Jan;221:107480. doi: 10.1016/j.rmed.2023.107480. Epub 2023 Dec 1.
Laboratory diagnosis and treatment of Mycoplasma pneumoniae infection in children: a review.
Gao L, Sun Y.
Ann Med. 2024 Dec;56(1):2386636. doi: 10.1080/07853890.2024.2386636. Epub 2024 Aug 3.
Mycoplasma pneumoniae and its role as a human pathogen.
Waites KB, Talkington DF.
Clin Microbiol Rev. 2004 Oct;17(4):697-728, table of contents. doi: 10.1128/CMR.17.4.697-728.2004.
Biomarkers associated with the diagnosis and prognosis of Mycoplasma pneumoniae pneumonia in children: a review.
Ding L, Jiang Y.
Front Cell Infect Microbiol. 2025 Mar 18;15:1552144. doi: 10.3389/fcimb.2025.1552144. eCollection 2025.
Mycoplasma pneumoniae.
Paquette M, Magyar M, Renaud C.
CMAJ. 2024 Sep 30;196(32):E1120. doi: 10.1503/cmaj.240085.
Neutrophil-to-lymphocyte ratio as a predictor of poor outcomes of Mycoplasma pneumoniae pneumonia.
Li D, Gu H, Chen L, Wu R, Jiang Y, Huang X, Zhao D, Liu F.
Front Immunol. 2023 Dec 19;14:1302702. doi: 10.3389/fimmu.2023.1302702. eCollection 2023.
A comparative study of general and severe mycoplasma pneumoniae pneumonia in children.
Yang S, Lu S, Guo Y, Luan W, Liu J, Wang L.
BMC Infect Dis. 2024 Apr 26;24(1):449. doi: 10.1186/s12879-024-09340-x.
Mycoplasma pneumoniae pneumonia.
Mansel JK, Rosenow EC 3rd, Smith TF, Martin JW Jr.
Chest. 1989 Mar;95(3):639-46. doi: 10.1378/chest.95.3.639.
